Search results
Showing 31 to 45 of 66 results for etanercept
Guselkumab for treating moderate to severe plaque psoriasis (TA521)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderate to severe plaque psoriasis in adults.
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)
Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA543)
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis in adults after inadequate response to DMARDs.
Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)
Evidence-based recommendations on enzyme-linked immunosorbent assay (ELISA) tests for therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors in
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis in adults.
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis in adults.
This guideline covers diagnosing and managing rheumatoid arthritis. It aims to improve quality of life by ensuring that people with rheumatoid arthritis have the right treatment to slow the progression of their condition and control their symptoms. People should also have rapid access to specialist care if their condition suddenly worsens.
Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)
Evidence-based recommendations on secukinumab (Cosentyx) for treating non-radiographic axial spondyloarthritis in adults.
Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)
Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults.
darbepoetin 2 June 2006 TA143 Ankylosing spondylitis - adalimumab, etanercept & infliximab 31 March 2008 TA010 Asthma (children under 5)...
Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (TA768)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active psoriatic arthritis in adults.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on bimekizumab (Bimzelx) for treating active psoriatic arthritis in adults.